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Quality of life assessment in heart failure interventions:
a 10-year (1996–2005) review
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The increasing prevalence and poor prognosis associated with heart failure have prompted research to focus on improving
quality of life (QoL) for heart failure patients. Research from 1996–2005 was systematically reviewed to identify randomized
controlled trials that assessed QoL in heart failure. In 120 studies, 44 were medication trials; 19 surgical/procedural
interventions; and 57 patient care/service delivery interventions. Studies were summarized in terms of aim, population, QoL
measures used and QoL findings. Studies used 47 different measures of QoL-generic, health-related, condition-specific,
domain-specific and utility measures. Most used a single QoL measure. In 87%, a condition specific QoL measure was
used, with the Minnesota Living with Heart Failure Questionnaire the favoured assessment tool. The range of QoL
measures in use poses challenges for development of cumulative knowledge. Although comparability across studies is
important, this must be informed by the responsiveness of the instrument selected. As carried out in other cardiac groups,
comparative evaluations of instrument responsiveness are needed in heart failure. Eur J Cardiovasc Prev Rehabil 00:000–
000 c 2007 The European Society of Cardiology
European Journal of Cardiovascular Prevention and Rehabilitation 2007, 00:000–000
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Introduction
Heart failure is associated with both high levels of
mortality and high healthcare costs. For instance, it
consumes an estimated 2–2.5% of the total health budget
in the United Kingdom [1]. Given the poor prognosis of
heart failure and the increasing complexity of manage-
ment regimens, much recent emphasis has focused on
maintaining or improving quality of life (QoL) for heart
failure patients. Early studies showed that heart failure
was associated with poorer QoL than other common
chronic conditions such as diabetes and chronic lung
disease [2]. Exponential growth has been seen in QoL
research in heart failure over the past decade. This overall
body of work has been reviewed on previous occasions,
most recently in 1999 [3] with a 2006 review of nursing
interventions in heart failure [4]. These reviews have
outlined a range of descriptive cross-sectional and
interventional studies. Owing to the many recent
developments in therapeutic options, including patient
care and service management approaches, and pharma-
cological and device innovations, many of the more recent
QoL studies are randomized interventions. As rando-
mized studies provide the most conclusive evidence, a
review of such studies can help clarify and consolidate
patterns of QoL findings from this active research area.
Defining QoL is a complex process that has been well
documented elsewhere [5]. A basic assumption was that
QoL assessment must be carried out by the patient him/
herself, as studies have demonstrated that patient
assessment does not correlate with physician assessment
[6]. Otherwise, QoL definition and/or operationalization
by study authors was accepted.
This paper thus reviewed randomized controlled trials
which assessed QoL in heart failure interventions, either
as a primary or secondary end point. The objective was to
describe the aim of each study, the sampling and
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assessment time frames, the specific instruments used to
assess QoL and the study’s key QoL findings.
Methods
The review involved systematic searches of the following
databases from January 1996 to December 2005: MED-
LINE, PsychINFO, and CINAHL. OVID in process and
other nonindexed citations for the period were also
searched.
The search terms used were ‘quality of life’, ‘heart
failure’, ‘measure/measurement’ and ‘assess/assessment’
combined in different ways to yield maximum results.
Truncated terms were used as appropriate for each
database. All terms were used as text words (i.e. words
appearing in the title or abstract, key words or a database
entry).
Inclusion/exclusion criteria
Papers were included in the review if the study was
designed as a randomized controlled trial of heart failure
patients; QoL was specifically stated to be a primary or
secondary outcome; a self-report measure of QoL was
used; and the study was published in English.
Results
A total of 233 studies were identified using the specified
search terms. Of these, 120 met the defined selection
criteria. Details of the QoL measures used in the studies
are provided in Table 1. Measures were categorized
according to whether their focus was generic (general
QoL), health-related (health-related QoL), condition-
specific (aspects of QoL relevant to particular health
problems), domain-specific (particular component of
QoL) or utility (the value of health or other interventions
in terms of a combination of increased QoL and length of
life) [5].
Eight studies used a generic QoL measure. The most
frequently used measure was Cantril’s ‘Ladder of Life’
(three studies) [27,60,61]. Health-related measures were
used in 46 studies. In the majority (52%), the measure of
choice was the 36-item Short-form Health Survey (SF-
36) or some subscale(s) of the SF-36 (24 studies) [61–
65,10,66–82]. In six studies, this was the only QoL
measure used. The next most commonly used measure
was the Sickness Impact Profile or a derivative (eight
studies) [63,83,8,84–88].
One hundred and five (87%) studies used a condition-
specific measure of QoL, with the majority favouring the
Minnesota Living with Heart Failure Questionnaire
(MLHF). This measure was used in 83 (69%) of all
studies [61–64,66,68,71,74,78–82,85,88–115,34,116–
155]. In 57 (47%) of studies, it was the only measure
used. The next most commonly used condition-specific
measures were the Chronic Heart Failure Questionnaire
(six studies) [75,83,156–159] and the Quality of Life
Index (four studies) [67,96,137,151].
Table 1 QoL measures used in randomized controlled studies of
heart failure 1996–2005
Category Measure N of
studies
Generic Ladder of Life [7] 3
Self-assessment of General Well-Being (SAGWB)
[8]
2
Scale of Life Satisfaction [9] 1
0–100 Global QoL scale [10] 1
Psychological General Well-Being Index (PGWB)
[11]
1
Health-related 36-Item Short-Form Health Survey (SF-36) [12,13] 24
Sickness Impact Profile (SIP) (also called Func-
tional Limitations Profile) [14]
8
Profile of Mood States (POMS) [15] 3
Nottingham Health Profile (NHP) [16,17] 2
Dartmouth COOP Functional Health Assessment
Charts (COOP Charts) [18]
1
The Psychological Adjustment to Illness Scale
(PAIS) [19]
1
Multidimensional Functional Assessment Ques-
tionnaire (OARS) [20]
1
The Functional Status Questionnaire [21] 2
Items to assess impact of illness on leisure and
regular activities [22]
1
Patients Global Assessment of Change in Quality
of Life (PGACQoL) [23]
1
General Health Questionnaire [24] 1
Health status index derived from SIP scores [22] 1
Condition-specific Minnesota Living With Heart Failure Questionnaire
(MLHF) [25]
83
Chronic Heart Failure Questionnaire (CHQ) [26] 6
Signs and symptoms of heart failure question-
naire(s)/scale(s) [27–29]
3
Quality of Life Index (QLI) [30] 4
Kansas City Cardiomyopathy Questionnaire
(KCCQ) [31]
1
QoL profile for chronic diseases (PLC) [32] 1
Heart Failure Functional Status Inventory [33] 1
Specific Symptoms Scale [34,35] 1
European Organisation for Research on Treatment
of Cancer QLQ C-30 (EORTC QLQ-C30) [36]
1
Subjective Symptoms Assessment Profile (SSA-P)
[37]
1
Customized – 16 items [38] 1
Customized – breathlessness, fatigue, well-bring
[39]
1
Domain-specific Sense of Coherence Scale (SOC) [40] 3
Yale Dyspnea–Fatigue Index [41] 1
Hospital Anxiety and Depression Questionnaire
(HADS) [42]
3
Centre for Epidemiological Studies Depression
Scale (CES–D) [43]
2
Heart Patients Psychological Questionnaire
(HPPQ) [44]
2
Epworth Sleepiness Scale [45] 1
Heart Failure Self-Efficacy Scale [46] 1
Guyatt Respiratory Scale [47] 1
The Transitional Dyspnea Index/Mahler Dyspnea–
Fatigue Index [48]
2
Philadelphia Geriatric Morale Score [49] 1
Zung Self-rated Depression Scale [50] 1
Geriatric Depression Scale [51,52] 1
The Functional Assessment of Chronic Illness
Therapy – Spiritual Well-being [53,54]
1
Specific Activities Scale [55] 2
Karolinska Scale (modified) [56] 1
State Anxiety Inventory [57] 1
State Anger Inventory [58] 1
Utility EuroQoL quality of life measure (EQ–5D) [59] 6
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A range of domain-specific measures was also used, the
most frequently used was the Sense of Coherence scale
(three studies) [84–86] and the Hospital Anxiety and
Depression Scale (three studies) [83,151,160]. The
EuroQoL quality of life measure, which combines
information on the absolute and relative value of aspects
of QoL, was the only utility-based measure of QoL used
in the studies reviewed. It was used in combination with
other measures in four studies [148,152,158,161] and
alone in two studies [162,163].
Most studies used a single measure of QoL (76 studies;
63%) (see Appendix A* for a detailed breakdown of the
combinations). Use of a single condition-specific measure
was the favoured approach to QoL measurement, with
the MLHF being used most frequently (76% of single
measure studies). Where multiple measures were used,
the most common combination consisted of a health-
related measure and either a condition-specific or a
domain-specific measure or both (23/43 studies). None of
the studies encompassed measures from all five cate-
gories examined.
In addition to be being categorized according to the
measure(s) used, studies were categorized according to
type of trial – pharmacological, surgical/procedural and
patient care and service management interventions.
Pharmacological trials
Of the 120 studies reviewed, 44 were medication trials
(see Table 2). Almost three quarters (80%) of the 44
pharmacological trials used the MLHF. In most (29/32) it
was the sole measure of QoL. A single measure of QoL
was used in 32 trials.
Of the 44 pharmacological trials, 27 evaluated the effects
of a medication compared with a placebo or usual care.
Ten trials reported a QoL benefit of medication over
placebo [72,90,92,93,96,99,100,124,155,162]. A partial
effect was reported in two studies [61,113]. Fifteen
reported no significant differences between medication
and placebo [39,63,78,89,101,106,107,111,129,133,139,
141,146,149,165]. Four studies were terminated early,
two because of a trend towards increased mortality in the
treatment arm [112,158], one because of significantly
increased survival in the treatment arm [125] and one for
reasons not outlined [147].
A number of trials compared the impact of two or more
medications on outcomes including QoL. In a comparison
of torsemide and furosemide [98], QoL was significantly
better in the torsemide group at one of three assessment
points.
Candesartan was found to improve QoL significantly
more than verapamil or placebo [103] and inotrope
infusions (milrinone or dobutamine) improved QoL
significantly when compared with placebo [102].
Studies comparing cilazapril and captopril [22], meto-
prolol and carvedilol [131], enalapril and losartan [140],
captopril and spirapril [167] and captopril and lisinopril
[28] found no difference in QoL scores between groups.
Two studies [88,163] compared losartan and captopril and
both found significant improvement in QoL within but
not between groups. Treatment guided by plasma
aminoterminal brain natriuretic peptide offered no QoL
benefits over treatment guided by standard care [94,120].
Konstam and colleagues [164] examined QoL data from
the SOLVD trial which compared enalapril with a
placebo. Baseline assessment of QoL predicted mortality
and heart failure-related hospitalizations in patients
randomized to enalapril and placebo treatment.
Surgical/procedural trials
Of 120 studies reviewed, 19 were surgical/procedural
trials (see Table 3). As with the pharmacological trials,
the favoured measure of QoL was the MLHF, used in
78% of surgical/procedural trials (15/19). Most studies
used a single measure of QoL (13/19).
Of the 19 interventions, 10 reported a positive impact of
the procedure (or at least one procedure of those
assessed) on the QoL score(s) of participants
[10,64,75,76,91,97,104,105,115,122,123]. Two studies
[97,105] were follow-ups on previously beneficial studies
to assess whether benefits initially observed were
sustained at 12 months. Two studies reported a partial
impact on QoL (i.e. a positive impact at some but not all
assessment time points) [116,122], whereas four reported
no measurable change in QoL [95,108,109,159]. One
study [10] evaluated the impact of three different
physiologic sensors in permanent pacemakers on cardio-
vascular events and QoL, and found that patients who
received one of the sensor types (blended) had
significantly poorer SF-36 physical function scale scores
than the other two groups.
Brignole and colleagues [168] completed a trial which
involved two phases. In phase one, right ventricular and
left ventricular pacing were compared. No significant
difference between group QoL scores was found,
although there was significant improvement within the
two groups on all QoL measures from baseline to end
point. In phase two, right ventricular and biventricular
pacing were compared. Again there was significant
improvement within the groups on all QoL measures
from baseline to end point. A between group difference
*See supplementary data.
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Table 2 Pharmacological (N=44)
Study Aim of study Na NYHA class Method/intervention Time-Frame (weeks)b QoL indicator QoL findingsc
Goldstein et al. [141] To assess the tolerability, safety, and
effect on left ventricular ejection frac-
tion of metoprolol
60 III–IV Metoprolol or placebo 26 MLHF No significant difference in QoL
Hjalmarson et al. [139] To assess the effects of metoprolol on
mortality, hospitalization, symptoms,
and QoL in patients with heart failure
(subset from MERIT-HF Trial)
741 II–IV Metoprolol or placebo 52 MLHF No significant difference in QoL
scores
RESOLVD Investigators
[129]
To assess the effects of metoprolol 426 II–IV Metoprolol or placebo 24 MLHF Metoprolol did not affect QoL
Sanderson et al. [131] To compare the long-term clinical efficacy
of metoprolol versus carvedilol
51 II–IV Metoprolol or carvedilol 12 MLHF Both medications significantly im-
proved symptoms (P<0.001). No
significant difference in QoL scores
Agostoni et al. [155] To assess the effects of b-blockers on
ventilation
15 II–III Carvedilol or placebo 26 (3 mths on each
regimen)
MLHF Carvedilol improved quality-of-life
scores (P<0.05)
Bristow et al. [149] To assess the efficacy and safety of
carvedilol
345 II–IV Carvedilol low, medium or
high dose or placebo
26 MLHF No significant changes in QoL scores
between groups
Cohn et al. [147] To assess the safety and efficacy of
carvedilol
131 II–IV Carvedilol or placebo 26 MLHF Study terminated early. QoL had
improved similarly in both groups
Colucci et al. [145] To assess if carvedilol inhibits clinical
progression in patients with mildly
symptomatic heart failure owing to left
ventricular systolic dysfunction
366 II–IV Carvedilol or placebo 52 MLHF No significant changes in QoL scores
between groups
Packer et al. [133] To assess the effects of carvedilol (The
PRECISE Trial)
278 II–IV Carvedilol or placebo 26 MLHF Carvedilol therapy had little effect on
indirect measures of patient benefit
including quality-of-life scores
Konstam et al. [164] To assess the independent relation of
QoL to mortality and congestive heart
failure-related hospitalizations in pa-
tients randomized to enalapril or pla-
cebo [Studies of Left Ventricular
Dysfunction (SOLVD) Trial]
2465 I–IV Enalapril or placebo 158 (mean follow-up) The Functional Status Ques-
tionnaire; POMS; SF-36
Baseline assessment of QoL pre-
dicted mortality and heart failure-
related hospitalizations in sympto-
matic and asymptomatic patients
randomized to enalapril and place-
bo treatment. But other domains
were stronger predictors
Guazzi et al. [140] To assess losartan and enalapril in
isolation or in combination
25 II–III Enalapril + placebo, losar-
tan +placebo, enala-
pril + losartan or the same
preparations in a reverse
order or placebo+place-
bo
8 MLHF No significant difference in QoL be-
tween groups
van den Broek et al.
[127]
To assess if duration of action of spirapril
compared with captopril affects clin-
ical efficacy
20 II–III Captopril or spirapril 12 MLHF No significant improvement in QoL
between groups
Cowley et al. [88] To compare QoL measures following
losartan or captopril in elderly symp-
tomatic heart failure patients
203 II–IV Losartan or captopril 48 MLHF; SIP Significant improvements in QoL from
baseline for both groups
(Pr0.001). Nonsignificant trend
favouring losartan vs. captopril for
composite QoL endpoint
Konstam et al. [163] To compare the effect of losartan with
captopril on mortality, morbidity and
functional status of patients [ELITE II
study] (QoL substudy)
1856 II–IV Losartan or captopril 52 EQ-5D Visual Analogue Scale QoL improved in both groups
(P<0.001) but did not differ be-
tween groups over time
Bulpitt et al. [22] To compare QoL effects of cilazapril or
captopril in patients with mild to
moderate heart failure
367 II–IV Cilazapril or captopril daily
for 24 weeks, or placebo
for 12 weeks followed by
cilazapril for 12 weeks
24 SIP; POMS; Dyspnea-Fatigue
Index; a health status index
derived from SIP scores;
items to assess impact of ill-
Nonsignificant trend towards im-
proved QoL on ACE inhibitors vs.
placebo
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Study Aim of study Na NYHA class Method/intervention Time-Frame (weeks)b QoL indicator QoL findingsc
health on regular and leisure
activities
Morisco et al. [28] To compare the efficacy, safety, and
tolerability of lisinopril with captopril in
elderly patients
251 II–III Lisinopril or captopril 12 Signs and symptoms of heart
failure
Similar improvement in both groups
Larsen et al. [165] To assess adaptive changes in acute
haemodynamic response to inhibitors
of angiotensin-converting enzyme
135 II–III Cilazapril 0.5mg, 1.0mg or
2.5mg or placebo
12 Questionnaire based on symp-
toms state, general well-
being and daily activities
The QoL assessment remained un-
changed or improved in the majority
of patients
Watson et al. [89] To assess the effect of coenzyme Q on
echocardiographic and haemodynamic
indexes of left ventricular ejection
fraction and on QoL in patients with
chronic left ventricular systolic dys-
function
30 NS Coenzyme Q or placebo 12 MLHF No significant difference in QoL with
coenzyme Q
Cohn et al. [113] To assess the effect of vesnarinone on
mortality and morbidity in severe heart
failure
833 III–IV Vesnarinone 30mg or
60mg or placebo
26 MLHF Significantly greater increase in QoL
in 60-mg vesnarinone group vs.
placebo group at 8 weeks
(P<0.001) and at 16 weeks
(P=0.003).Similar but not signifi-
cant trends in QoL in the 30-mg
vesnarinone group
Dorszewski et al. [112] To assess the effects of urapidil com-
bined therapy on QoL, exercise toler-
ance and haemodynamic parameters
36 III–IV Urapidil or placebo 12 MLHF Study terminated early. A trend to-
wards increased mortality in urapidil
group was observed
Hutcheon et al. [78] To assess the effects of perindopril on 6-
min walking distance and QoL in very
old patients with left ventricular systo-
lic dysfunction
66 I–IV Perindopril or placebo 10 MLHF; SF-36 No significant improvement in QoL
Keith et al. [107] To assess whether vitamin E supple-
mentation modifies oxidative stress in
patients with advanced heart failure.
56 III–IV Vitamin E or placebo 12 MLHF No significant difference in QoL be-
tween groups.
Lader et al. [61] To assess the effect of digoxin therapy on
QoL [QoL substudy of the Digitalis
Investigation Group (DIG) trial]
589 I–IV Digoxin or placebo 52 SF-36; Ladder of Life; CES-D;
State Anxiety Inventory; State
Anger Inventory; MLHF
Perceived health was improved in
digoxin group at 4 months
(P=0.0057). No significant differ-
ences at 52 weeks
Levine et al. [106] To assess the effect of mibefradil on
morbidity and mortality congestive
heart failure
327 II–IV Mibefradil or placebo 52 MLHF QoL virtually unchanged in both
groups
Lubsen et al. [101] To assess the effect of pimobenda on
exercise capacity (PICO trial)
317 II–III Pimobendan or placebo 24 MLHF No significant effects over time or
difference in QoL across groups
Mancini et al. [99] To assess the effect of erythropoietin
(EPO) on exercise performance in
anaemic heart failure patients.
26 III–IV EPO or placebo 12 MLHF QoL decreased in control group and
increased in the treatment group
Majani et al. [100] To assess the effect of valsartan on QoL -
Valsartan Heart Failure Trial (Val-HeFT)
3010 IV Valsartan or placebo 156 MLHF Significant effect of Valsartan on
overall MLHF score (P=0.005).
Placebo group slowed as the trial
progressed
Newby et al. [166] To assess the effect of candoxatril on
exercise capacity, clinical status and
QoL in patients receiving angiotensin-
converting enzyme inhibition
110 I–III Candoxatril or placebo 12 Questionnaire assessing
breathlessness, fatigue and
well-being
No significant changes in QoL scores
between groups
Omran et al. [72] To compare the effectiveness of oral D-
ribose supplementation on cardiac
haemodynamics and QoL in patients
with chronic coronary artery disease
and heart failure
15 II–III D-ribose or placebo 7 SF-36 D-ribose demonstrated a significant
improvement in QoL (Pr0.01)
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Udelson et al. [63] To assess the effect of amlodipine as
adjunctive therapy
437 II–IV Amlodipine or placebo 12 MLHF; SF-36; SIP (subscale) Amlodipine did not affect QoL
Webster et al. [93] To investigate whether sildenafil is safe
and effective for erectile dysfunction
35 II–III Sildenafil or placebo 12 MLHF MLHF index improved with sildenafil
(P=0.02)
Zeng, Zeng and Li [90] To assess the efficacy and safety of
berberine
156 II–IV Berberine or placebo 8 (treatment) 104 (mean
follow-up)
Dyspnea-Fatigue Index; MLHF Significant difference in the aggregate
score on the index and MLHF after
8 weeks of treatment (P<0.02)
Elkayam et al. [111] To assess the effect of organic nitrates in
patients treated with angiotensin-con-
verting enzyme inhibitiors
29 II–III Transdermal nitroglycerin or
placebo
12 MLHF No significant differences changes in
QoL
Lee et al. [124] To assess the effect of perhexiline 56 II–III Perhexiline or placebo 8 MLHF Significantly improved MLHF scores
with Perhexiline (P=0.04). No
change in control MLHF scores
Little et al. [103] To compare candesartan and verapamil 21 7 III–IV Candesartan, verapamil or
placebo
6 MLHF Significant improvement in QoL with
candesartan (P<0.05) but not with
verapamil
Witte et al [162] To access the effect of micronutrient
supplementation on QoL and left
ventricular function in elderly patients
30 NS Micronutrient supplement or
placebo
39 EQ-5D Significant effect of micronutrients on
QoL (P<0.05), decrease in QoL of
placebo patients (P=0.23)
Lopez-Candales et al.
[102]
To assess the safety and efficacy of
outpatient inotrope infusions in in-
tractable heart failure
29 III–IV Intravenous milrinone, dobu-
tamine or placebo
12 MLHF Significant improvement in QoL (P<
0.00001) with inotrope infusions
Noe et al. [98] To assess the effect of torsemide and
furosemide
240 II–III Torsemide or furosemide 26 MLHF QoL significantly better for torsemide
group at month 4 (P=0.017), but
not at month 2 (P=0.059) or
month 6 (P=0.269)
Taylor et al. [125] To assess the effect of fixed-dose com-
bination isosorbide dinitrate-hydrala-
zine (ISND-HYD) in an African-
American population with advanced
heart failure
1050 III–IV Fixed-dose ISDN-HYD or
placebo
MLHF Terminated early as a result of sig-
nificantly increased survival in the
treatment arm (P=0.02)
Califf et al. [158] To assess the effect of epoprostenol [The
Flolan International Randomized Survi-
val Trial (FIRST)]
471 III–IV Epoprostenol infusion or
usual care
Terminated early Signs and symptoms question-
naire; EQ-5D; CHQ; NHP
Study terminated early. Strong trend
toward decreased survival on epo-
prostenol
Yancy et al. [92] To assess the safety and feasibility of
serial infusions of nesiritide (from the
FUSION I trial)
210 III–IV Weekly infusions of nesiri-
tide or usual care
12 MLHF Significant improvement in QoL be-
tween groups at 4, 8 and 12 weeks
Prasun et al. [96] To assess the effect of a patient-directed
flexible diuretic protocol
66 II–IV Flexible diuretic titration (DT)
or usual care
12 MLHF; QLI Significant increase in DT total QOL
score (P=0.001) only
Troughton et al. [94] To assess the treatment of heart failure
guided by plasma aminoterminal brain
natriuretic peptide (N-BNP) concen-
trations
69 II–IV Treatment guided by either
plasma N-BNP concen-
tration or standard care
26–41.2 (follow-up) MLHF No significant difference in QoL
Beck–da–Silva [120] To compare brain natriuretic peptide
(BNP) guided therapy and expert
clinical assessment
41 II–IV Bisoprolol increased ac-
cording to BNP levels or
according to clinical as-
sessment
13 MLHF QoL improved in both groups. Non-
significant trend towards greater
improvement in the BNP group
CES-D, Centre for Epidemiological Studies Depression Scale; CHQ, Chronic Heart Failure Questionnaire; EQ-5D, EuroQoL Quality of Life measure; MLHF, Minnesota Living with Heart Failure Questionnaire; NHP, Nottingham
Health Profile; PGWB, Psychological General Well-Being Index; POMS, Profile of Mood States; QLI, Quality of Life Index; SF-36, Medical Outcomes 36-Item Short-Form General Health Survey; SIP, Sickness Impact Profile.
aReported as presented in paper (in some cases this is number recruited, in some the number completing the study). bReported as presented in paper (in some cases run-in period is included). cP values provided where
reported.
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Table 3 Surgical/procedural (N=19)
Study Aim of study Na NYHA Class Method/intervention Time-Frame
(weeks)b
QoL indicator QoL findingsd
Auricchio et al. [122] To assess the clinical efficacy of single-
site left ventricular pacing and deter-
mine the impact of baseline conduction
delay severity on the magnitude of
benefit
86 II–IV Long QRS or short QRS compared
during a 3-month period of active
pacing and a 3-month period of in-
active pacing
52 MLHF Significant improvement in QoL in long
QRS group (P=0.004)
Auricchio et al. [121] To compare the short-term and long-term
effects of atrial synchronous preexcita-
tion of one or both ventricles
41 III–IV 4 weeks of treatment with biventricular or
univentricular stimulation, followed by 4
weeks without treatment, and then 4
weeks of treatment with the opposite
stimulation.
26 MLHF Significant QoL improvement after treat-
ment (P<0.001). No change after
following no training period. Nonsigni-
ficant increase in QoL after second
treatment period
Brignole et al. [168] To compare right ventricular (RV) vs. left
ventricular (LV) pacing and RV vs.
biventricular (BiV) pacing
56 I–III 3-month crossover comparison between
RV and LV and between RV and BiV
12 MLHF; Spe-
cific Symp-
toms
Scale;
modified
Karolinska
Scale
RV and LV: no difference between
groups, significant improvement in both
groups on all measures from baseline
to end point
RV and BiV: significant difference be-
tween groups on Karolinska scores
only, significant improvement in both
groups on all measures from baseline
to end point
Cazeau et al. [115] To assess the effect of multisite biven-
tricular pacing in heart failure with
intraventricular conduction delay
67 III 3-month period of inactive pacing and a
3-month period of active pacing
30 MLHF QoL score improved significantly with
active pacing (P<0.001)
Lamas et al. [76] To compare dual-chamber and single-
chamber pacing
2010 I + Dual-chamber pacing or ventricular pa-
cing
260 SF-36; Spe-
cific Activ-
ity Scale
Significant improvement from baseline to
48months on both SF-36 summary
scores. No in specific activity scale
scores
Linde et al. [105] To assess the impact of biventricular
pacing on QoL [MUltisite STimulation
In Cardiomyopathy (MUSTIC) Trial]
131 III Comparison of biventricular pacing and
inactive pacing (patients in sinus
rhythm) or biventricular pacing and
right univentricular inhibited pacing
(VVIR)
52 MLHF Improved QoL with biventricular pacing
Linde et al. [104] To assess whether the benefits of BiV
pacing observed during the crossover
phase of the MUSTIC trial were
sustained over 12 months
131 III 52 MLHF Significant improvement in QoL in SR
group (P=0.0001) and AF group
(P=0.002)
Aranda et al. [123] To assess whether patients who have
conduction abnormalities other than
left bundle-branch block (LBBB) re-
spond favourably to cardiac resyn-
chronization therapy (CRT)
[MultiCentre InSync Randomized Clin-
ical Evaluation (MIRACLE)]
394 III–IV LBBB or right bundle-branch block
(RBBB) or interventricular conduction
delay (IVCD)
26 MLHF Significant improvement QoL with CRT
for patients with IVCD only (P=0.038)
Higgins et al. [108] To assess the safety and effectiveness of
CRT combined with an implantable
cardiac defibrillator (ICD)
490 II–IV CRT/ICD or control Up to 26 MLHF No significant improvement in QoL
Young et al. [91] To assess the efficacy and safety of
combined CRT and ICD therapy in
patients with congestive heart failure
on optimal therapy (MIRACLE)
369 III–IV ICD activated, CRT on or ICD activated,
CRT off (control)
26 MLHF Significant improvement in QoL with CRT
(P=0.02)
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QoL indicator QoL findingsd
Calvert et al [148] To assess the QoL of patients from the
CArdiac REsynchronicsation in Heart
Failure (CARE-HF) STUDY
813 III–IV Cardiac resynchronization or control
(check)
QoL assessed at
13 & will be assed
at 78
MLHF; EQ-
5D
Results demonstrated an association
between EQ-5D and MLHF scores
Mansfield et al. [75] To compare the effect of obstructive
sleep apnea (OSA) treatment with
nocturnal continuous positive airway
pressure (CPAP)
55 II–IV CPAP or control 12 CHQ; SF-36;
Epworth
Sleepiness
Scale
Significant improvement in four SF-36
subscales; three domains of the CHQ
and Epworth Sleepiness Scale score in
with CPAP compared with control
Bradley et al. [159] To evaluate the effects of continuous
positive airway pressure (CPAP) in
patients with central sleep apnea and
heart failure
258 II–IV CPAP or control QoL Assessments
at 12, 26 and 104
CHQ No significant difference in QoL between
groups
Park et al. [97] To assess the effect of a left ventricular
assist device (LVAD) on survival and
QoL and to determine outcome im-
provement [extended follow-up of The
Randomized Evaluation of Mechanical
Assistance for the Treatment of Con-
gestive Heart Failure (REMATCH) Trial]
129 IV LVAD therapy or optimal medical man-
agement (OMM)
52 & 104 follow-
up
MLHF MLHF scores were significantly better for
LVAD (P=0.007)
Stevenson et al. [64] To assess outcomes in patients under-
going inotropic infusions assigned to
LVAD or optimal medical management
(OMM) [REMATCH]
129 IV LVAD or OMM 52 MLHF; SF-
36 (physi-
cal func-
tion and
emotional
role sub-
scales)
After LVAD, QoL scores for survivors
improved
Torre-Amione, et al. [95] To assess the effect of an immune
modulation therapy
75 III–IV Immune modulation therapy or placebo 26 MLHF Nonsignificant trend toward improvement
in QoL with treatment
Shukla et al. [10] To compare the impact of three different
physiologic sensors in permanent pa-
cemakers on cardiovascular events
and QoL [The Mode Selection Trial
(MOST)]
1245 III–IV Pacemaker with accelerometer, piezo-
electric crystals or blended sensors
208 SF-36; Spe-
cific activ-
ities scale;
0–100 glo-
bal QoL
scale
Significantly poorer physical function with
blended sensors (P<0.01)
Gilligan et al. [109] To assess whether ‘optimal’ AV delay
results in a symptomatic and functional
benefit greater than that provided by
the device’s normal AV delay
17 II–III ‘Optimum’ AV delay or control 12 MLHF No significant improvement in QoL
Binanay et al. [169] To assess the effect of pulmonary artery
catheterization [ESCAPE trial]
433 NS Therapy guided by clinical assessment
and Pulmonary artery catheters (PACs)
or clinical assessment alone
26 MLHF MLHF scores improved in both groups at
1month, greater improvement with
PAC. At 6months clinical assessment
scores improved to match PAC scores.
CHQ, Chronic Heart Failure Questionnaire; MLHF, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association; SF-36, Medical Outcomes 36-Item Short-Form General Health Survey. aReported as
presented in paper (in some cases this is number recruited, in some the number completing the study). bReported as presented in paper (in some cases run-in period is included). cP values provided where reported.
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Table 4 Patient Care and Service Management Interventions (N=57)
Study Aim of study N NYHA
class
Method/intervention Time-frame
(weeks)a
QoL indicator QoL findingsb
Exercise/cardiac rehabilitation interventions
Belardinelli et al. [119] To assess the effect on functional capa-
city, QoL, and clinical outcome of
exercise training (ET)
99 II–IV Exercise or control 61 MLHF Significant improvement in MLHF at 2
months with training (P=0.001). Im-
provement remained stable after 12
months and during follow-up
Beniaminovitz et al. [117] To compare the effects of exercise train-
ing and relaxation techniques in pa-
tients with moderate to severe heart
failure
29 NS Isolated lower-limb training or
learned guided imagery relaxa-
tion technique (control)
12 MLHF; Guyatt Respiratory Scale;
The Transitional Dyspnea Index
Significant improvement in all QoL scores
with training (all P<0.05)
Gary et al. [110] To compare the effect of education only
with education and exercise in older
women with diastolic heart failure
32 II–III Home-based, low-to-moderate in-
tensity exercise and education
programme or education only
programme (control)
12 MLHF; Geriatric Depression
Scale
Significant improvement in QoL in inter-
vention and control groups (P=0.002;
P=00.24, respectively). Significantly
greater improvement with intervention
compared with control
Giannuzzi et al. [29] To assess the effect of exercise training
on LV remodelling in chronic heart
failure [The Exercise in Left Ventricular
Dysfunction and Chronic Heart Failure
(ELVD-CHF) Trial]
90 II–III Training or control 26 Modified likert symptom question-
naires
Significant improvement in QoL with
training (P<0.01) compared with con-
trol
Gottlieb et al. [81] To assess the effect of exercise training
on peak performance and QoL in
elderly patients
33 II–III Exercise or control 26 MLHF; SF-36; Functional Status
Questionnaire; CES-D
No significant improvement in QoL
Johnson et al. [170] To assess the effect of a domiciliary
inspiratory muscle training on exercise
tolerance and QoL
18 II–III Training group or control group 8 16-item questionnaire No significant improvement in QoL
Keteyian et al. [138] To assess the effect of exercise training
on chronotropic incompetence
51 men II–III Exercise training or control 24 MLHF No significant improvement in QoL.
Koukouvou et al. [137] To assess the physiological and psycho-
social effects of exercise training
26 men II–III Exercise or control 26 MLHF; QLI; Scale of Life Satis-
faction
Trained patients demonstrated a signifi-
cant improvement in QoL
Nuhr et al. [135] To assess the effect of chronic low-
frequency electrical stimulation (CLFS)
of thigh muscles on muscle perfor-
mance and QoL
32 II–IV CLFS or control 10 MLHF (German) Significant improvement in QoL in the
CLFS group compared with control
(P<0.001)
Oka et al. [156] To assess the effect of a home-based
combined walking and resistance ex-
ercise program on symptoms and QOL
40 women II–III Exercise programme or usual care 12 CHQ Exercisers reported improvement in fati-
gue (P=0.02), emotional functioning
(P=0.01) and sense of mastery
(P=0.04)
Owen and Croucher [134] To assess the effect of an exercise
programme on older heart failure pa-
tients
22 I–IV Exercise or control 12 MLHF No significant improvement in MLHF
scores
Parnell et al. [132] To assess the effect of an exercise
training programme on arterial me-
chanical properties, LV performance
and QoL
21 II–III Training or control 8 MLHF Significantly improved QoL following the
exercise training programme (P=0.01)
Pozehl et al. [71] To assess the adjunctive effect of an
exercise training intervention vs. stan-
dard pharmacologic therapy
23 II–IV Exercise or usual care 12 SF-36; POMS; MLHF Significantly higher role function
(P<0.05), role emotional (P<0.001)
and mental functioning (P<0.01) and
significantly better scores on POMS
confusion/bewilderment subscale with
training. No significant difference in
MLHF
Quittan et al. [69] To assess the effect of a programme of
neuromuscular stimulation of thigh
muscles on strength and cross-sec-
42 II–1V Stimulation or control group 8 SF-36 Significantly improvement on SF-36 phy-
sical functioning, emotional role and
social functioning subscales (all
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Study Aim of study N NYHA
class
Method/intervention Time-frame
(weeks)a
QoL indicator QoL findingsb
tional area in patients with refractory
heart failure listed for transplantation
P<0.05). No change in QoL in con-
trols
Quittan et al. [70] To assess the effect of an exercise
programme on QoL in patients with
severe chronic heart failure
27 II–III Training or control 12 SF-36 (German) QoL improved significantly in the domains
of vitality (P=0.0001), physical role
fulfilment (P=0.001), physical
(P=0.02) and social (P=0.0002)
functioning with training
Tyni-Lenne et al. [84] To compare the effect of endurance
training with knee extensor muscles on
exercise tolerance and QoL
21 men II–III Two leg training, one leg training
or control
8 SIP; SOC Training improved overall QoL (P<0.05).
Compared with the control group, the
improvement was more pronounced in
the two-leg training group (P 0.02–
0.005) as compared with the one-leg
training group (NS). No change in SOC
scores
Tyni-Lenne et al. [85] To compare exercise training on a cycle
ergometer; aerobic knee-extensor
training and usual care in previously
trained patients
24 II–III Cycle ergometer or knee-extensor
training or control
8 MLHF; SIP; SOC Significant improvement in MLHF scores
(P<0.05) only after knee-extensor
training. Three of the four assessed SIP
scales also showed a nonsignificant
trend toward improvement after train-
ing. SOC remained stable.
Tyni-Lenne et al. [86] To assess the effect of skeletal muscle
endurance training in women with
chronic congestive heart failure sec-
ondary to either ischemic or idiopathic
dilated cardiomyopathy
16 women II–III Crossover trial with 8 weeks of
knee extensor training and 8
weeks of nontraining.
16 (exclud-
ing run-in)
SIP; SOC Improvement on overall (P<0.01) and
psychosocial (P<0.03) QoL with
training. No change in SOC
van den Berg-Emons et al.
[128]
To assess if aerobic training leads to a
more active lifestyle and improved QoL
34 II–III Training or control group 12 MLHF (Dutch) Slight but not significant improvement in
QoL in the training group
Wielenga et al. [8] To assess the effect of exercise training
on QoL
67 II–III Training or control 12 SIP; SAGWB; HPPQ Significantly lower scores on Feelings of
Being Disabled (HPPQ subscale) in
the training group compared with con-
trol (P=0.042). Significantly higher
SAGWB scores after training
(P<0.0000) were observed after
training
Wielenga et al. [171] To assess the safety and efficacy of
physical training [result of the Chronic
Heart Failure and Graded Exercise
study (CHANGE)]
80 II–III Endurance (levels A, B and C)
training or control
12 SAGWB; HPPQ Nonsignificant difference between
changes in scores on ‘feelings of being
disabled’ subscale in the groups
(P=0.06). Within the training group,
the difference between levels was
significant in relation to this subscale
(P<0.01). Patient overall assessment
of general well-being was significantly
improved in both groups (P<0.0001).
Improvement in patients assessment of
QoL in both groups (P<0.0001)
Willenheimer et al. [172] To assess if post-training effects on
physical function and QoL are sus-
tained
54 NS Exercise programme or control 43 PGACQoL No significant improvement in QoL
Witham et al. [83] To assess the effect of a seated exercise
programme on physical function and
health status in frail patients with heart
failure
82 II–III Gentle, seated exercise program
or usual care
26 CHQ; HADS; Philadelphia Geria-
tric Morale Score; the modified
Functional Limitations Profile
(UK version of SIP)
No significant improvement in QoL
Belardinelli et al. [118] To assess the effect of exercise training
on sexual dysfunction in patients with
heart failure
59 II–III Exercise or control 8 MLHF QoL improvised significantly with training,
compared with control (P<0.001)
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Study Aim of study N NYHA
class
Method/intervention Time-frame
(weeks)a
QoL indicator QoL findingsb
Austin et al. [152] To assess the impact of a cardiac
rehabilitation programme
200 II–III Cardiac rehabilitation programme
or usual care
24 MLHF; EQ-5D Significant improvement in MLHF and
EuroQoL between groups (P<0.001)
Klocek et al. [173] To assess the effect of physical training
on oxygen consumption and QoL
42 II–III Constant workload or progres-
sive/increasing workload or
control
26 PGWB; SSA-P Significant improvement in PGWB scores
in the intervention groups (P<0.01).
Significant
Improvement in 4/6 (constant workload),
5/6 (progressive workload) and 2/6
SSA-P dimensions.
Collins et al. [82] To assess the effect of a cardiac rehabi-
litation programme
31 men I–III Moderate intensity supervised
aerobic exercise program or
control
12 MLHF; SF-36 Significant improvement in perceived
physical function (P=0.025) after ex-
ercise. No significant difference in
MLHF scores between groups
Service delivery interventions
Artinian et al. [154] To assess the effect of a self-care and
medication compliance device, linked
to a web-based monitoring system
18 II–III Compliance device and usual
care or usual care
12 MLHF Significantly more improvement in QoL
after monitoring (P=0.006)
Atienza et al. [153] To assess the effect of a discharge and
outpatient management programme for
hospitalized patients
338 III–IV Comprehensive discharge plan-
ning and close follow-up or
usual care
52 MLHF QoL improved in both groups but im-
provement was significantly greater for
intervention compared with control
(P=0.01)
Ducharme et al. [174] To assess the effect of a multidisciplinary
heart failure clinic
230 II–IV Follow-up at multidisciplinary
specialized out-patient clinic or
usual care
26 MLHF Significant improvement in emotional and
physical QoL scores in the intervention
group compared to control (P<0.001)
Ojeda et al. [126] To assess whether the benefits of a
discharge planning intervention were
sustained 12 months after the end of
the study
153 II–IV Discharge planning or usual care 52 weeks
after study
end
MLHF QoL benefits reported at end of study not
present at follow-up
Benatar et al. [151] To compare the effect of care delivered by
home nurse visit (HNV) and nurse
telemanagement (NTM)
216 III–IV HNV or NTM 12 MLHF; QLI-Cardiac version;
HADS; Heart Failure Self-effi-
cacy Scale
Significant improvement in QoL and self-
efficacy in both groups (P<0.01). Non
significant trend toward more QoL
improvement with NTM compared with
HNV
Bouvy et al. [150] To assess the effect of a pharmacist-led
intervention on medication adherence
in patients with heart failure
152 I–IV Intervention or usual care 26 MLHF; COOP WONCA
CHARTS
Disease-specific QoL improved in both
groups. Non significant trend towards
more improvement with usual care.
Generic QoL improved with usual care
and worsened with intervention
De Lusignan et al. [157] To assess the effect of home telemoni-
toring
20 I–IV Telemedicine or control 52 (initially
13mths)
General Health Questionnaire;
CHQ
No significant differences in QoL
Sadik et al. [68] To assess the effect of a pharmacist-led
pharmaceutical care programme
208 I–IV Structured pharmaceutical care
programme or usual care
Assess-
ment every
13 weeks
for 52
weeks
MLHF; SF-36 Significantly improved MLHF and some
SF-36 subscale scores with interven-
tion compared to control (P<0.05)
Feldman et al. [143] To assess the effect of a home health
intervention designed to standardize
nursing care, strengthen nurses’ sup-
port for patient self-management and
yield better CHF patient outcomes.
371 NS Evidence-based nursing protocol,
patient self-care guide and
training to improve nurses’
teaching and support skills or
control
13 MLHF No significant differences in QoL
Feldman et al. [161] To compare the impact and cost-effec-
tiveness of two information-based pro-
vider reminder interventions designed
to improve self-care management and
outcomes
628 NS E-mail to the patient’s nurse high-
lighting 6 HF-specific clinical
recommendations (basic) or in-
itial nurse reminder with addi-
tional clinician and patient
resources (augmented) or usual
care
6.4 KCCQ; EQ-5D Improved QoL (KCCQ) with both inter-
ventions compared to usual care
(Pr0.05). Basic intervention also
yielded a higher EuroQoL score relative
to usual care (Pr 0.05).
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Method/intervention Time-frame
(weeks)a
QoL indicator QoL findingsb
GESICA Investigators
[175]
To assess the effect of a centralized
telephone intervention on death or
hospital admission rates
1518 I–IV Counselling and monitoring by
nurses through frequent tele-
phone follow-up or usual care
26 (min) MLHF Significantly better QoL after intervention
(P=0.001)
Harrison et al. [79] To assess the effect of transitional care on
QoL, rates of readmission and emer-
gency room use for hospitalized pa-
tients
Intervention focused on the tran-
sition from hospital-to-home
and supportive care for self-
management 2 weeks after
hospital discharge
12 MLHF; SF-36 Significantly better MLHF scores at 6 wks
(P=0.002) and 12 wks (P=0.001)
after discharge with transitional care.
No between group differences on SF-
36 scores
Jaarsma et al. [27] To assess the effect of a supportive
educational nursing intervention on
self-care abilities, self-care behavior,
and QoL of patients with advanced HF
179 III–IV Systematic education and nursing
support in hospital and at home
or usual care
39 Heart Failure Functional Status
Inventory; Symptom question-
naire; PAIS; Ladder of life
No significant improvement in QoL
LaFramboise et al. [77] To compare a heart failure disease man-
agement programme through an in-
home telehealth communication device
(Health Buddy) with traditional home
management strategies
90 NS Same educational content deliv-
ered differently to each group-
telephonic, home visit, health
buddy and home visit/health
buddy groups.
8.5 SF-36 No significant differences in QoL
Martensson et al. [74] To assess the effect of a nurse-led
intervention to improve self-manage-
ment
153 III-IV Patient and family education and
monthly telephone follow-up or
control
52 MLHF; SF-36; Zung self rated
depression scale
Significant improvement at 3mths in SF-
36 role function with intervention
(P=0.008). This improvement did not
persist at 12mths. No other improve-
ments, control group QoL deteriorated
significantly on a number of SF-36
dimensions. Significant difference in
moderate and severe depression from
baseline to 3mths (P=0.023) with
patients in the intervention group hav-
ing significantly less depression. AT
12mth follow-up there was no differ-
ence between groups.
Mejhert et al. [176] To assess the effect of a nurse based
outpatient management programme for
elderly patients
208 II–IV Follow-up within the management
programme or usual follow-up
78 NHP No significant improvement in QoL.
Naylor et al. [136] To assess the effect of a transitional care
intervention delivered by advanced
practice nurses (APNs) to older hospi-
talized heart failure patients
239 NS APN-directed discharge planning
and home follow-up protocol or
control
52 MLHF Short-term improvements in overall QoL
(12 weeks, P<0.05), physical dimen-
sion of QoL (2 weeks, P<0.01; 12
weeks, P<0.05) and patient satisfac-
tion (2 and 6 weeks, P<0.001) with
intervention only
Noel et al. [98] To assess the effect of home telehealth on
healthcare costs and QoL for elderly
high resource users with complex
comorbidities
104 NS Home telehealth or control 52 OARS Multidimensional Func-
tional Assessment (cognitive
status, functional level, patient
satisfaction and self-rated
health)
The intervention group showed improved
cognitive status at 12months
(P<0.028). Patient satisfaction scores
improved significantly in the control
group at 3months (P<0.001) and
6months (P<0.004) compared with
the interventions group (P<0.0001)
Oddone et al. [73] To assess the effect of enhanced access
to primary care on diagnostic evalua-
tion, pharmacologic management and
health outcomes in hospitalized pa-
tients
443 I–IV Enhanced access to primary care
or usual care
26 SF-36 No significant differences in QoL. Hospi-
tal readmissions increased with inter-
vention.
Philbin et al. [60] To assess the effect of a regional, multi-
hospital, collaborative quality improve-
ment intervention on care and
outcomes
1504 Mean 3.3 Hospital Quality improvement in-
tervention or usual care
26 Ladder of Life No significant improvement in QoL
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Method/intervention Time-frame
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QoL indicator QoL findingsb
Scott et al. [67] To assess the effect of mutual goal setting
and supportive-educative nursing inter-
ventions on mental health and QoL
88 NS Supportive/educative intervention
or mutual goal setting interven-
tion or control
26 QLI; SF-36 (MHI-5 subscale only) Significant improvement in QoL with both
interventions (P=0.006; P=0.000).
Significantly higher QoL scores in goal
setting intervention group (P=0.01).
No change in control group
Sethares and Elliott [130] To assess the effect of a tailored message
intervention on heart failure readmis-
sion rates, QoL, and health beliefs
70 NS Tailored message during hospita-
lization, one week and 1 month
after discharge or control
5 MLHF No significant difference in QoL
Gwadry–Sridhar et al. [80] To assess the effect of an educational
intervention in hospitalized heart failure
patients
134 NS In hospital educational interven-
tion delivered by a multidisci-
plinary team or usual care
QoL as-
sessed
every 13
for 52
MLHF; SF-36 QoL improved in both groups over time.
The only between group difference
favoured the intervention (MLHF
scores) (P=0.04)
Shively et al. [66] To assess the effect of behavioural
management
116 I–III Behavioural management pro-
gram or usual care
69 MLHF; SF-36 Significantly improved MLHF physical
dimension scores over time compared
with intervention (P=0.009)
Smith et al. [65] To assess the effect of disease manage-
ment on QoL
1069 I–IV Disease management or augmen-
ted disease management or
control
78 (follow-
up)
SF-36 No effect of disease management ob-
served across any of the SF-36 com-
ponents
Varma et al. [62] To assess the effect of a structured
pharmaceutical care programme for
elderly patients on disease control,
QoL, and use of healthcare facilities
83 I–IV Education from a pharmacist or
usual care
52 MLHF; SF-36 Significantly better MLHF scores at
9months (P=0.04) (not baseline, 3, 6
or 12months) with education. Signifi-
cantly better physical function scores at
9 (P=0.009) and 12months
(P=0.03); vitality at 12months
(P=0.04); social functioning at
12months (P=0.015) and mental
health at 9 and 12months (both
P=0.014) with education
Paes [160] To assess the effect of a palliative care
clinic on QoL
13 III–IV Palliative care intervention or
usual care
22 EORTC QLQ-C30 (European Or-
ganisation for Research on
Treatment of Cancer QLQ C-
30); HADS
Nonsignificant improvement in interven-
tion group in HADS and QoL scores
Relaxation-based interventions
Chang et al. [177] To assess the effect of a relaxation
response (RR) intervention on the QoL
and exercise capacity
95 II–III Weekly RR group and home
practice or weekly cardiac
education (EDU) or usual care
15–19
week fol-
low-up
MLHF; The Functional Assess-
ment of Chronic Illness Therapy
– Spiritual Well-Being
The RR group had significantly better
QoL change scores in peace-spiritual
scales than did the UC group
(P=0.02). No significant difference
was observed between the EDU and
UC groups. Insignificant trend towards
improved d in emotional QoL with RR.
No significant intervention effect on
physical QoL
Curiati et al. [145] To assess the effect of meditation on
sympathetic activation and QoL in an
elderly group
19 I–II Meditation or control 12 weeks
(after
2mths)
MLHF Improved QoL with meditation (P=0.02)
compared to control
Michalsen et al. [178] To assess the effect of hydrotherapy 15 II–III Intensive home-based hydrother-
apy or restriction crossover
6 Quality of life profile for chronic
diseases
Significant improvement in 3 of 6 QoL
dimensions and significant reduction in
heart-failure related symptoms with
hydrotherapy (Pr0.05)
AGWB, Self-Assessment of General Well-Being; CES-D, Centre for Epidemiological Studies Depression Scale; CHQ, Chronic Heart Failure Questionnaire; COOP WONCA Charts, Dartmouth COOP Functional Health
Assessment Charts/WONCA; EORTC QLQ-C30, European Organisation for Research on Treatment of Cancer QLQ C-30; EQ-5D, EuroQoL Quality of Life measure; HADS, Hospital Anxiety and Depression Questionnaire;
HPPQ, Heart Patients Psychological Questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHF, Minnesota Living with Heart Failure Questionnaire; NHP, Nottingham Health Profile; OARS, OARS
Multidimensional Functional Assessment (cognitive status, functional level, patient satisfaction and self-rated health); PAIS, Psychological Adjustment to Illness Scale; PGACQoL, Patients Global Assessment of Change in
Quality-of-Life; QLI, Quality of Life Index; SF-36, Medical Outcomes 36-Item Short-Form General Health Survey; SIP, Sickness Impact Profile; SOC, Sense of Coherence Scale; SSA-P, Subjective Symptoms Assessment Profile.
aReported as presented in paper (in some cases run-in period is included). bP values provided where reported.
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was found in Karolinska scores only, favouring biventri-
cular pacing.
Finally Calvert and colleagues [148], using data from the
ongoing CARE-HR study, found an association between
EQ-5D and MLHF scores.
Patient care and service management interventions
The remaining 57 studies concerned patient care and
service management interventions (see Table 4). Again,
the most frequently used measure of QoL was the
MLHF, which was used in 56% of studies (32/57).
Twenty-seven studies involved cardiac rehabilitation
programmes or exercise/muscle stimulation interventions.
The majority (20/27 studies) reported a positive impact
of an intervention on one or more dimensions of QoL
when compared with usual care [8,69–71,82,84–
86,110,118,119,132,135,137,152,156,171,173,29]. Seven
reported no significant QoL effect of the intervention/
programme [38,81,83,128,134,138,172].
Service delivery interventions, including discharge and
outpatient management programmes and education-
based interventions were evaluated in 27 studies. Twelve
studies reported a positive impact of one or more
interventions on one or more dimensions of QoL when
compared with usual care. These interventions were
based on multidisciplinary approaches to patient treat-
ment [144], transitional care [79,136], discharge and
outpatient management [153], behavioural management
[66], information provision (basic and augmented levels),
nurse-led education [74], in-hospital education [80],
pharmacist-led education [62,68], compliance monitoring
[154] and telephone counselling and monitoring [142].
In comparing two methods of care delivery (nurse
telemanagement and home nurse visit), Benatar et al.
[151] found that QoL improved with both methods, with
a trend towards better improvement in the nurse
telemanagement group. A comparison of an education
intervention, a mutual goal setting intervention and a
control, found improvement in QoL in both intervention
groups, with the improvement being significantly greater
for the mutual goal setting intervention [67].
Nine of the interventions reported no significant QoL
effect [27,60,65,77,130,143,157,160,176]. Ojeda and col-
leagues [126] completed a 12-month follow-up of a study
reporting beneficial effects of a discharge intervention
and found that the benefits were not present at follow-
up. Three studies noted mixed results. Bouvy and
colleagues [150] evaluated a pharmacist-led intervention
on medication adherence and reported that although
condition-specific QoL improved in both the usual care
and intervention groups, generic QoL improved with
usual care and worsened with intervention. Oddone and
colleagues [73] evaluated the effect of increased access to
primary care than in usual care and found no significant
differences in QoL between groups. An increase in
hospital admission, however, was seen with the interven-
tion. Finally, in a study assessing the effect of a home
telehealth intervention, the intervention group showed
improved cognitive status on the OARS Multidimen-
sional Functional Assessment, whereas patient satisfac-
tion scores improved significantly more in the control
group compared with the intervention group [179].
This category also included three relaxation-based inter-
ventions. A positive impact on one or more dimensions of
QoL was reported for a meditation intervention
[145,161], a hydrotherapy intervention [178] and a
relaxation response programme [177].
Discussion
Much recent research on heart failure has focused on
maintaining or improving QoL. This review identified
120 randomized controlled trails that assessed QoL in
this patient group – 44 medication trials, 19 surgical
interventions and 57 patient and service management
interventions. A wide range of generic, health-related,
condition-specific, domain-specific and utility assessment
tools were used.
The majority of studies used a single measure of QoL.
This approach was particularly favoured in medication
trials and surgical interventions. In patient management
and service delivery interventions, there was an even split
between the number of studies using one or multiple
QoL measures.
Excluding the studies terminated early, and the study
that looked at the predictive value of QoL scores, the
majority of medication trials reported no significant
between-group differences in QoL. In contrast, the
majority of surgical interventions reported a positive
effect on QoL. The majority of patient care and service
management interventions also reported positive effects
of the intervention on QoL.
The studies reviewed used a total of 47 self-report tools
to assess QoL. The large range of measures available
presents challenges to the selection of the most
appropriate, reliable and valid instrument for a particular
context [180,181]. One criterion for instrument selection
is comparability. The MLHF is currently the clear choice
based on this criterion given its widespread use.
Responsiveness, however, is also important. The selection
of a measurement instrument can play an important role
in finding out whether and to what extent differences
between randomized groups are evident. Detailed
comparative studies of measures are warranted in existing
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or planned heart failure studies in which more than one
QoL instruments may be used.
In conclusion, QoL is now a widely used outcome
measure in randomized trials of heart failure interven-
tions. Interventions focusing on surgical procedures or
patient care/service management interventions appear to
deliver a greater benefit regarding QoL than those
focusing on pharmacological interventions. The latter,
however, mostly involve comparisons across medication
categories rather than placebo/intervention comparisons.
Greater agreement on key QoL outcome measures would
enable cross-intervention-type comparisons and a greater
understanding of the documented improvements in QoL
for patients.
Supplementary data
Supplementary data are available at The HJR Journal
Online (’’’).
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Appendix A
Complete profile of measures used in randomized controlled studies of heart failure 1996–2005
Generic Health-related Condition-specific Domain-specific Utility
1 Ladder of Life
6 SF-36
1 PGACQoL
1 NHP
1 OARS
1 The Functional Status Ques-
tionnaire
POMS
SF-36
57 MLHF
2 CHQ
2 Signs and symptoms of heart
failure questionnaire(s)/
scale(s)
1 PLC
1 Customized 16 item question-
naire
1 Customized – general well-
being, daily activities, symp-
toms
1 Customized – breathlessness,
fatigue, well-being
1 MLHF
QLI
1 EQ-5D
1 Ladder of Life SF-36 MLHF CES-D
State Anxiety Questionnaire
State Anger Questionnaire
1 Ladder of Life PAIS Signs and symptoms of heart
failure questionnaire(s)/
scale(s)
Heart Failure Functional Status
Inventory
1 SAGWB SIP HPPQ
1 0-100 Global QoL Scale SF-36 Specific Activities Scale
1 Scale of Life Satisfaction MLHF
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Generic Health-related Condition-specific Domain-specific Utility
QLI
1 PGWB SSA-P
1 SAGWB HPPQ
1 SIP (subscale) MLHF
SF-36
1 SIP CHQ HADS
Philadelphia Geriatric Morale
1 SIP MLHF SOC
1 SF-36 MLHF Zung Self-Rated Depression Scale
1 SF-36 MLHF CES-D
Functional Status Questionnaire
1 NHP CHQ EQ-5D
Signs and symptoms of heart
failure questionnaire(s)/
scale(s)
8 SF-36 MLHF
1 SIP MLHF
1 COOP Charts MLHF
1 SF-36 QLI
1 General Health Questionnaire CHQ
1 SF-36 MLHF
POMS
1 SF-36 CHQ Epworth Sleepiness Scale
2 SIP SOC
1 SIP Dyspnea–Fatigue Index
POMS
Health Status Index
Items to assess impact of
Illness on leisure and regular
activities
1 SF-36 Specific Activities Scale
1 MLHF Karolinska Scale
Specific Symptoms Question-
naire
1 MLHF Dyspnea–Fatigue Index
1 Signs and symptoms of heart
failure questionnaire(s)/
scale(s)
Dyspnea–Fatigue Index
1 MLHF The Functional Assessment of
Chronic Illness Therapy – Spiri-
tual Well-Being
1 MLHF Geriatric Depression Scale
1 MLHF Guyatt Respiratory Scale
The Transitional Dyspnea Index
1 MLHF HADS
QLI Heart Failure Self-Efficacy Scale
1 EORTC QLQ-C30 HADS
2 MLHF EQ-5D
1 KCCQ EQ-5D
CES-D, Centre for Epidemiological Studies Depression Scale; CHQ, Chronic Heart Failure Questionnaire; EORTC QLQ-C30, European Organisation for Research on
Treatment of Cancer QLQ C-30; EQ-5D, EuroQoL Quality of Life measure; HADS, Hospital Anxiety and Depression Questionnaire; HPPQ, Heart Patients Psychological
Questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHF, Minnesota Living with Heart Failure Questionnaire; NHP, Nottingham Health Profile; OARS,
OARS Multidimensional Functional Assessment (cognitive status, functional level, patient satisfaction and self-rated health); PAIS, Psychological Adjustment to Illness
Scale; PGACQoL, Patients Global Assessment of Change in Quality-of-Life; QLI, Quality of Life Index; SF-36, Medical Outcomes 36-Item Short-Form General Health
Survey; SIP, Sickness Impact Profile; SOC, Sense of Coherence Scale; SSA-P, Subjective Symptoms Assessment Profile.
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